ICD-10 category · Chapter I · B20-B24
B21 Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms
8 codes under B21 in the South African Master Industry Table 2021, 7 valid for clinical use; 7 marked as a Prescribed Minimum Benefit.
| Code | Description | Use | Benefits |
|---|---|---|---|
| B21 | Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms | Heading only | — |
| B21.0 | HIV disease resulting in Kaposi's sarcoma | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.1 | HIV disease resulting in Burkitt lymphoma | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.2 | HIV disease resulting in other types of non-Hodgkin lymphoma | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.3 | HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic and related tissue | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.7 | HIV disease resulting in multiple malignant neoplasms | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.8 | HIV disease resulting in other malignant neoplasms | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
| B21.9 | HIV disease resulting in unspecified malignant neoplasm | Valid · may be primary | PMB 168S # HIV-infection · # HIV voluntary counseling and testing Co-trimoxazole as preventative therapy Screening and preventative therapy for TB, Diagnosis and treatment of sexually transmitted infections Pain management in palliative care Treatment of opportunistic infections, Prevention of mother-to-child transmission of HIV Post-exposure prophylaxis following occupational exposure or sexual assault Medical management and medication, including the provision of anti-retroviral therapy, and ongoing monitoring for medicine effectiveness and safety, to the extent provided for in the national guidelines applicable in the public sector |
Prescribed Minimum Benefits in B21. A medical scheme must fund the diagnosis, treatment and care of a PMB condition in full, within its rules on designated providers and treatment protocols. The PMB code and treatment component beside each code come from the Council for Medical Schemes’ PMB Coded List; the scheme decides whether a given claim qualifies.
Source and terms
Reproduced from the national table, unaltered.
The Department publishes the table for the industry to load. The ICD-10 Master Industry Table page
Codes and descriptions: ICD-10 Master Industry Table (MIT) 2021, published 16 March 2021 by the National Department of Health, Republic of South Africa. ® National Department of Health: all rights reserved. Reproduced for reference without alteration.
ICD-10 is the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, © World Health Organization. The WHO ICD-10 descriptions appear as published in the MIT.
Prescribed Minimum Benefit (PMB) and Chronic Disease List (CDL) markers: Council for Medical Schemes, PMB Coded List, as read by GreenNotes. Benefit decisions rest with each medical scheme.
Source file: ICD-10_MIT_2021_Excel_16-March_2021.xlsx. Found an error in a code or description? Write to help@greennotes.co.za.
This lookup is a reference to the published code table, not coding advice. Code assignment is the treating practitioner’s responsibility, following the South African ICD-10 Coding Standards and Guidelines and the WHO ICD-10 volumes. GreenNotes does not warrant that the table is complete or current.
This is the South African table. Most ICD-10 results online are the United States’ ICD-10-CM, a different code set that South African medical schemes do not accept. Regulation 5 of the General Regulations under the Medical Schemes Act requires the diagnostic code on every account, and the Master Industry Table is the list it is coded from.
In GreenNotes
Code the consultation once. The invoice and the claim pick it up.
GreenNotes looks codes up from this same table while you write the consultation. The codes you record there, including any the clinical AI included for your review, carry into the invoice and the medical-aid claim.